AbCellera Biologics Inc. (ABCL): R&D Expense
$186.83M
Year ended 2025-12-31
$197.77M
Trailing 12 months to 2026-06-30
+20.1%
3-year compound annual growth
+44.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $186.83M | +11.7% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $167.26M | -4.8% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $175.66M | +62.8% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $107.88M | +73.8% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $62.06M | +111.1% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $29.39M | +190.6% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $10.11M | n/a | 2022-02-25, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $186.83M | +11.7% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $240.28M | +38.9% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $104.00M | -5.1% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
Compare ABCL, CTMX, BCYC, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗